Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy

The endothelin axis, recognized for its vasoconstrictive action, plays a central role in the pathology of pulmonary arterial hypertension (PAH). Treatment with approved endothelin receptor antagonists (ERAs), such as bosentan, ambrisentan, or macitentan, slow down PAH progression and relieves sympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Enevoldsen, Frederik C., Sahana, Jayashree, Wehland, Markus, Grimm, Daniela, Infanger, Manfred, Krüger, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141375/
https://www.ncbi.nlm.nih.gov/pubmed/32197449
http://dx.doi.org/10.3390/jcm9030824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141375/
https://www.ncbi.nlm.nih.gov/pubmed/32197449
http://dx.doi.org/10.3390/jcm9030824

Ejemplares similares